HIT 4T Score
বিস্তারিত গাইড শীঘ্রই আসছে
HIT 4T Score (Heparin)-এর জন্য একটি বিস্তৃত শিক্ষামূলক গাইড তৈরি করা হচ্ছে। ধাপে ধাপে ব্যাখ্যা, সূত্র, বাস্তব উদাহরণ এবং বিশেষজ্ঞ পরামর্শের জন্য শীঘ্রই আবার দেখুন।
The 4T Score is a validated clinical prediction rule used to estimate the pre-test probability of Heparin-Induced Thrombocytopenia (HIT) — a serious, immune-mediated adverse drug reaction to heparin that, paradoxically, causes thrombosis rather than bleeding. HIT is caused by IgG antibodies against complexes of platelet factor 4 (PF4) and heparin, which activate platelets, generating thrombin and leading to venous and arterial thrombosis in up to 50% of untreated patients. The 4T Score was developed by Lo et al. and validated across multiple populations. It evaluates four clinical criteria, each scored 0–2, for a maximum total of 8 points. The four 'T' criteria are: Thrombocytopenia (severity and characteristics of platelet count fall), Timing (when the platelet count fall occurred relative to heparin exposure), Thrombosis (whether new thrombosis or other sequelae have developed), and oTher causes (whether alternative explanations for thrombocytopenia are present). A total score of 0–3 indicates low pre-test probability (<1% HIT), where anti-PF4 antibody testing is not required and heparin can generally continue. A score of 4–5 indicates intermediate probability (~10% HIT), where PF4 antibody testing is mandatory and heparin should be stopped pending results. A score of 6–8 indicates high pre-test probability (~50% HIT), where heparin must be stopped immediately, alternative non-heparin anticoagulation started (argatroban, fondaparinux, or danaparoid), and anti-PF4 antibody testing sent urgently. HIT carries a 30-day mortality of 5–10% if untreated and up to 20% limb amputation rate from thrombosis.
4T Score = Thrombocytopenia (0–2) + Timing (0–2) + Thrombosis (0–2) + oTher causes (0–2); Total 0–8 Where each variable represents a specific measurable quantity in the health and medical domain. Substitute known values and solve for the unknown. For multi-step calculations, evaluate inner expressions first, then combine results using the standard order of operations.
- 1Score Thrombocytopenia: 2 points = fall >50% and nadir ≥20 × 10^9/L; 1 point = fall 30–50% or nadir 10–19 × 10^9/L; 0 points = fall <30% or nadir <10 × 10^9/L.
- 2Score Timing of platelet fall: 2 points = onset day 5–10 (or ≤1 day if prior heparin within 30 days); 1 point = onset >10 days or unclear timing; 0 points = onset ≤4 days without recent heparin exposure.
- 3Score Thrombosis: 2 points = new thrombosis confirmed, skin necrosis, or acute systemic reaction after heparin bolus; 1 point = progressive or recurrent thrombosis, or erythematous skin lesions; 0 points = no thrombosis.
- 4Score oTher causes of thrombocytopenia: 2 points = no other cause evident; 1 point = possible other cause; 0 points = definite other cause (sepsis, post-transfusion, DIC).
- 5Sum all four domains: 0–3 = low probability; 4–5 = intermediate probability; 6–8 = high probability.
- 6If score ≥4: immediately stop all heparin products (including heparin flushes and LMWH); start non-heparin anticoagulation; send anti-PF4/heparin antibody test (ELISA); consider functional assay (SRA — serotonin release assay) for confirmation.
- 7If HIT confirmed: avoid warfarin until platelet count recovers to ≥150 × 10^9/L (warfarin in active HIT can cause venous limb gangrene); screen for occult thrombosis with duplex ultrasound of bilateral lower limbs.
Stop all heparin immediately; start argatroban; send anti-PF4 ELISA urgently; duplex USS bilateral legs
Maximum 4T score of 8 confirms high pre-test probability. Do not wait for antibody results — initiate non-heparin anticoagulation now.
HIT unlikely; continue heparin; monitor platelets; treat sepsis
The early timing (day 2 without prior heparin exposure) and clear alternative explanation (sepsis) make HIT unlikely. Antibody testing is not required.
Stop LMWH; start fondaparinux; send anti-PF4 ELISA; do not restart heparin until HIT excluded
An intermediate score of 5 requires antibody testing and heparin cessation. Fondaparinux is a safe alternative as cross-reactivity with HIT antibodies is rare.
Skin necrosis at heparin injection sites is a hallmark of HIT and scores 2 in the thrombosis domain
Skin necrosis at injection sites is pathognomonic of a delayed-type HIT reaction and should always trigger a high 4T score and immediate management.
Professionals in health and medical use Hit 4T Score as part of their standard analytical workflow to verify calculations, reduce arithmetic errors, and produce consistent results that can be documented, audited, and shared with colleagues, clients, or regulatory bodies for compliance purposes.
University professors and instructors incorporate Hit 4T Score into course materials, homework assignments, and exam preparation resources, allowing students to check manual calculations, build intuition about input-output relationships, and focus on conceptual understanding rather than arithmetic.
Consultants and advisors use Hit 4T Score to quickly model different scenarios during client meetings, enabling real-time exploration of what-if questions that would otherwise require returning to the office for detailed spreadsheet-based analysis and reporting.
Individual users rely on Hit 4T Score for personal planning decisions — comparing options, verifying quotes received from service providers, checking third-party calculations, and building confidence that the numbers behind an important decision have been computed correctly and consistently.
Extreme input values
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in hit 4t score calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Assumption violations
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in hit 4t score calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Rounding and precision effects
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in hit 4t score calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
| Domain | Score 2 | Score 1 | Score 0 |
|---|---|---|---|
| Thrombocytopenia | |||
| Timing | Day 5–10 (or ≤1d if prior heparin 5–30d) | >10 days or unclear; or within 1d if prior heparin 30–100d | ≤4 days without recent prior heparin |
| Thrombosis | New proven thrombosis; skin necrosis; acute systemic reaction | Progressive/recurrent thrombosis; erythematous skin lesions | None |
| oTher causes | No other cause apparent | Other possible cause | Definite other cause present |
Why does HIT cause thrombosis rather than bleeding?
HIT antibodies (IgG against PF4-heparin complexes) bind to platelets via Fc receptors and simultaneously activate platelets powerfully. This activation causes massive thrombin generation. The resulting hypercoagulable state leads to venous and arterial thrombosis. Paradoxically, despite a low platelet count, the risk is thrombosis, not bleeding, because the platelets are being consumed in forming clots rather than simply being absent.
Which alternative anticoagulants are used when HIT is suspected?
First-line non-heparin anticoagulants for suspected or confirmed HIT include: argatroban (direct thrombin inhibitor, hepatically cleared — preferred in renal failure), fondaparinux (synthetic pentasaccharide, renally cleared — off-label but widely used), and danaparoid (heparanoid — not available in all countries). Bivalirudin is an alternative in cardiac surgery. Direct oral anticoagulants (rivaroxaban, apixaban) are used for transition once acute HIT is treated.
Why should warfarin be avoided in acute HIT?
Warfarin inhibits proteins C and S (natural anticoagulants) before it inhibits the pro-coagulant factors II, VII, IX, and X. In the context of HIT, where thrombin generation is massively elevated, this transient protein C/S deficiency can cause venous limb gangrene — a devastating complication of starting warfarin too early in HIT. Warfarin should only be started once the platelet count has recovered to ≥150 × 10^9/L.
What is the anti-PF4 ELISA and what does a positive result mean?
The anti-PF4/heparin ELISA detects IgG (and sometimes IgM/IgA) antibodies against complexes of platelet factor 4 and heparin. It is highly sensitive (~97%) but only moderately specific (~74%) for HIT. A positive ELISA means PF4 antibodies are present but does not confirm HIT clinically. The serotonin release assay (SRA) or heparin-induced platelet activation (HIPA) test provides functional confirmation and higher specificity. Most patients with positive ELISA but low 4T score do not have clinical HIT.
What is the timing of platelet recovery after heparin cessation in HIT?
Hit 4T Score is a specialized calculation tool designed to help users compute and analyze key metrics in the health and medical domain. It takes specific numeric inputs — typically drawn from real-world data such as measurements, rates, or quantities — and applies a validated mathematical formula to produce actionable results. The tool is valuable because it eliminates manual calculation errors, provides instant feedback when exploring different scenarios, and serves as both a decision-support instrument for professionals and a learning aid for students studying the underlying principles.
Can patients with previous HIT receive heparin again?
Once HIT antibodies disappear (usually 3–6 months after the index event), a single unavoidable exposure during cardiac surgery (where heparin is essential for cardiopulmonary bypass) may be possible with close monitoring. Systemic anticoagulation with heparin should not be resumed in HIT-positive patients. LMWH cross-reacts with HIT antibodies and is also contraindicated.
Does fondaparinux cross-react with HIT antibodies?
Fondaparinux does not bind PF4 and does not form the PF4-heparin complex that triggers HIT antibody formation. Cross-reactivity with pre-existing HIT antibodies is extremely rare. This makes fondaparinux a safe and effective alternative anticoagulant in patients with suspected or confirmed HIT, though its use in HIT is technically off-label in most countries.
How does HIT differ from LMWH-associated thrombocytopenia?
All heparins (UFH and LMWH) can cause HIT, but the risk is lower with LMWH (incidence ~0.1–0.8%) than with unfractionated heparin (UFH, incidence 1–3%). Fondaparinux has essentially zero HIT risk. The 4T Score applies to both UFH and LMWH exposures. Once HIT antibodies develop to UFH, LMWH is cross-reactive and cannot be used.
প্রো টিপ
Remember the 4T mnemonic for both the score domains AND the key action: if 4T Score ≥6: Stop heparin, Send anti-PF4 antibody, Start alternative anticoagulant (argatroban/fondaparinux), Screen for occult thrombosis — the '4 S's of HIT management'.
আপনি কি জানেন?
HIT was first described in 1958 by Weismann and Tobin as 'white clot syndrome' — because the arterial thrombi formed are unusually white and platelet-rich (unlike the usual red, fibrin-rich venous clots), giving the syndrome a distinctive appearance at surgery. This paradox — a low platelet count causing white platelet-rich clots — remains one of the most counter-intuitive phenomena in clinical medicine.
তথ্যসূত্র
- ›Lo GK et al — Evaluation of the 4Ts Score for HIT (J Thromb Haemost 2006)
- ›Cuker A et al — 4Ts Score for HIT (Ann Intern Med 2012)
- ›ASH Clinical Practice Guidelines for HIT (2018)
- ›Warkentin TE — HIT: Recognition, Treatment, and Prevention (Chest 2005)
- ›Linkins LA et al — ASH HIT Guidelines (Blood Advances 2018)